Table 2 Overview of osteopontin levels measured with commercially available ELISA systems in healthy controls, malignant and benign diseases.
assay | material | patient group (n) | osteopontin mean ± SD (ng/ml) | osteopontin median (range) (ng/ml) | ref. |
|---|---|---|---|---|---|
Assay Designs (B1) | citrate plasma | head and neck cancer (54) von Hippel Lindau disease (31) healthy controls (15) | 447 (261–843) 318 (233–461) | 450 | [1] |
plasma | head and neck cancer (320) | -- | 113 (12–1382) | [2] | |
plasma | nasopharyngeal cancer healthy controls | 184.6 (6.8–856.9) 75.9 (10–455) | -- -- | [18] | |
EDTA plasma | multiple sclerosis – relapsing patients (30) healthy controls (10) | -- -- | 280 174 | [17] | |
serum | ovarian cancer (51) healthy controls (28) | 49 11 | -- -- | [19] | |
IBL (B2) | serum | pleural mesothelioma (76) asbestos-related non-malignant disease (69) healthy controls (45) | 133 ± 10 30 ± 3 20 ± 4 | -- -- -- | [5] |
EDTA plasma | esophageal carcinoma (103) | -- | 606 (82.8–1980) | [20] | |
plasma | ovarian cancer (51) healthy controls (107) | 486.5 147.1 | -- -- | [21] | |
plasma | ovarian cancer (38) | -- | 178 (12–3468) | [22] | |
serum | ovarian cancer, post-surgery (267) healthy controls (67) | 74 ± 116 147 ± 192 | 25 (25–671) 85 (25–617) | [23] | |
heparin plasma | non-small lung cancer (158) benign pulmonary disease (54) healthy controls (25) | 356.2 175.6 29.5 | 319.1 (16–1600) 161.6 (1.3–442.8) 17.9 (0–102.8) | [24] | |
EDTA plasma | coronary artery disease (107) healthy controls (71) | 616 ± 308 443 ± 237 | -- -- | [16] | |
EDTA plasma | interstitial pneumonia (17) healthy controls (20) | 945 ± 256 156.7 ± 52.2 | -- -- | [15] |